Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
Thursday, November 30, 2023Alvotech a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced today positive topline results from a pharmacokinetic
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin for Patients with Previously Treated Non-Small Cell Lung Cancer
Thursday, November 30, 2023AbbVie announced today topline results from the singlearm Phase LUMINOSITY trial evaluating telisotuzumabvedotin TelisoV in patients with cMet protein overexpression epidermal growth factor receptor
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
Wednesday, November 29, 2023Carisma Therapeutics Inc a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies today announced the clearance
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
Wednesday, November 29, 2023Evaxion Biotech AS a clinicalstage TechBio company specializing in developing AIImmunology powered vaccines proudly announces the presentation
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
Tuesday, November 28, 2023INmune Bio Inc a clinical stage immunology company dedicated to advancing treatments that leverage the patients innate immune system to combat disease
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
Tuesday, November 28, 2023SpringWorks Therapeutics Inc a commercialstage biopharmaceutical company focused on severe rare diseases and cancer announced today that the US Food and Drug Administration
Dupixent® Shows Promising Results in Second Phase 3 COPD Trial, Nearing FDA Submission as Potential First Approved Biologic
Monday, November 27, 2023Regeneron Pharmaceuticals Inc and Sanofi today announced that the second Dupixent investigational Phase chronic obstructive pulmonary disease trial showed that Dupixent
Vertex Extends KAFTRIO® Application for Cystic Fibrosis and Rare Mutations with EMA Validation
Monday, November 27, 2023Vertex Pharmaceuticals today announced that the European Medicines Agency has validated a Type II variation application to the Marketing Authorization for KAFTRIO
Novo Nordisk Invests More Than 16 Billion Danish Kroner in Expansion of Production Facilities in Chartres, France
Friday, November 24, 2023Novo Nordisk today announced the investment of more than billion Danish kroner starting in to expand the existing production site in Chartres France for the current and future product
Sandoz Launches Hyrimoz® (Adalimumab) High-concentration Formulation in Europe, Aiming to Improve Patient Care
Wednesday, November 22, 2023Sandoz the global leader in generic and biosimilar medicines today announces the launch of Hyrimoz citratefree high concentration formulation HCF mgmL in Europe The medicine
